Clinical Outcomes of Patients with Vogt–Koyanagi–Harada Disease Over 12 Years at a Tertiary Center

References

• Rao NA, Inomata H, Moorthy RS. Vogt–Koyanagi–Harada syndrome. In: Pepose J, Holland GN, Wilhelmus K, eds. Ocular Infection and Immunity. St Louis (MO): Mosby; 1996:734–753
   Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol. 1995;39:265–292
   PubMed Web of Science ®Google Scholar
• Kondo I, Yamagata K, Yamaki K, et al. Analysis of the candidate antigen for Harada’s disease. Nippon Ganka Gakkai Zasshi. 1994;98:596–603
   PubMedGoogle Scholar
• Sugita S, Sagawa K, Mochizuki M, et al. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt–Koyanagi–Harada disease. Int Immunol. 1996;8:799–803
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt–Koyanagi–Harada disease. Br J Ophthalmol. 1996;80:1002–1008
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–652
   PubMed Web of Science ®Google Scholar
• Ohno S, Char DH, Kimura SJ, et al. Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol. 1977;83:735–740
   PubMed Web of Science ®Google Scholar
• Rosen E. Uveitis, with poliosis, vitiligo, alopecia and dysacusia (Vogt–Koyanagi syndrome). Arch Ophthalmol. 1945;33:281–292
   Web of Science ®Google Scholar
• Minakawa R, Ohno S, Hirose S, et al. Clinical manifestation of Vogt–Koyanagi–Harada’s disease. Jpn J Clin Ophthalmol. 1985;39:1249–1253
   Google Scholar
• Tabbara KF, Chavis PS, Freeman WR. Vogt–Koyanagi–Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76:723–726
   PubMedGoogle Scholar
• Abu El-Asrar AM, Al-Kharashi AS, Al Dibhi H, et al. Vogt–Koyanagi–Harada disease in children. Eye. 2008;22:1124–1131
   PubMed Web of Science ®Google Scholar
• Al-Kharashi AS, Al Dibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2007;27:201–210
   PubMedGoogle Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2001;131:599–606
   PubMed Web of Science ®Google Scholar
• Kitamura M, Takami K, Kitachi N, et al. Comparative study of two sets of criteria for the diagnosis of Vogt–Koyanagi–Harada’s disease. Am J Ophthalmol. 2005;139:1080–1085
   PubMed Web of Science ®Google Scholar
• Yamaki K, Hara K, Sakuragi S. Application of revised diagnostic criteria for Vogt–Koyanagi–Harada disease in Japanese patients. Jpn J Ophthalmol. 2005;49:143–148
   PubMed Web of Science ®Google Scholar
• Bykhovskaya I, Thorne JE, Kempen JH, et al. Vogt–Koyanagi–Harada disease: clinical outcomes. Am J Ophthalmol. 2005;140:674–678
   PubMed Web of Science ®Google Scholar
• Urzua CA, Velasquez V, Sabat P, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2015; Jan 7. doi: 10.1111/aos.12648. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rajendram R, Evans M, Rao NA. Vogt–Koyanagi–Harada disease. Int Ophthalmol Clin. 2005;45:115–134
   PubMedGoogle Scholar
• Read RW, Rao NA, Cunningham ET. Vogt–Koyanagi–Harada disease. Curr Opin Ophthalmol. 2000;11:437–442
   PubMedGoogle Scholar
• Rathinam SR, Vijayalakshmi P, Namperumalsamy P, et al. Vogt–Koyanagi–Harada syndrome in children. Ocul Immunol Inflamm. 1998;6:155–161
   PubMed Web of Science ®Google Scholar
• Khairallah M, Zaouali S, Messaoud R, et al. The spectrum of Vogt–Koyanagi–Harada disease in Tunisia, North Africa. Int Ophthalmol. 2007; 27:125–130
   PubMedGoogle Scholar
• Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt–Koyanagi–Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007; 27:117–123
   PubMedGoogle Scholar
• Sukavatcharin S, Tsai JH, Rao NA. Vogt–Koyanagi–Harada disease in Hispanic patients. Int Ophthalmol. 2007; 27:143–148
   PubMedGoogle Scholar
• Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt–Koyanagi–Harada’s disease. Jpn J Ophthalmol. 1988;32:334–343
   PubMed Web of Science ®Google Scholar
• Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt–Koyanagi–Harada disease. Ophthalmology. 2010;117:591–599
   PubMed Web of Science ®Google Scholar
• Alam M1, Iqbal M, Khan BS, et al. Vogt Koyanagi Harada disease: treatment and visual prognosis. J Coll Physicians Surg Pak. 2013;23:740–742
   PubMed Web of Science ®Google Scholar
• Zhang M1, Liu Q, Min H, et al. Vogt–Koyanagi–Harada syndrome: glucocorticoid therapy and visual prognosis. Zhonghua Yan Ke Za Zhi. 2002;38:200–203
   PubMedGoogle Scholar
• Yamanaka E1, Ohguro N, Yamamoto S, et al. Evaluation of pulse corticosteroid therapy for Vogt–Koyanagi–Harada disease assessed by optical coherence tomography. Am J Ophthalmol. 2002;134:454–456
   PubMed Web of Science ®Google Scholar
• Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2006;142:119–124
   PubMed Web of Science ®Google Scholar
• Sonoda S, Nakao K, Ohba N. Extensive chorioretinal atrophy in Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol. 1999;43:113–119
   PubMed Web of Science ®Google Scholar
• Rubsamen PE, Gass JD. Vogt–Koyanagi–Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–687
   Google Scholar
• Cuchacovich M, Solanes F, Diaz G, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2010;18:200–207
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2007;15:381–387
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt–Koyanagi–Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87–90
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2012;90:603–608
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
   PubMed Web of Science ®Google Scholar
• Andrasch RH, Burns RP. Immunosuppressive therapy in severe chronic uveitis. Arch Ophthal. 1978;96:247–251
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Radwan A, Lebanan MO, et al. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt–Koyanagi–Harada syndrome. Ocul Immunol Inflamm. 2013;21:47–52
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt–Koyanagi–Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–614
   PubMed Web of Science ®Google Scholar
• Keino H, Goto H, Usui M. Sunset glow fundus in Vogt–Koyanagi–Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2002;240:878–882
   PubMed Web of Science ®Google Scholar
• Yang P, Sun M. Band-shaped keratopathy in Chinese patients with Vogt–Koyanagi–Harada syndrome. Cornea. 2011;30:1336–1340
   PubMed Web of Science ®Google Scholar